...of neutrophils to endothelial cells Indication: Treat psoriasis Endpoint: Safety, tolerability, pharmacokinetics Status: PDLI partner Scil Biomedicals GmbH...

...of neutrophils to endothelial cells Indication: Treat psoriasis Endpoint: Safety, tolerability, pharmacokinetics Status: PDLI partner Scil Biomedicals GmbH...

...superfamily. SCIL will have rights to market the jointly-owned product worldwide. Biopharm GmbH, Heidelberg, Germany Scil Biomedicals GmbH...

...$17 million in exchange for co-promotion rights in the U.S. Medarex Inc. (MEDX), Princeton, N.J. Scil Biomedicals GmbH...

...is required. Medarex Inc. , which last week partnered its MDX-RA and MDX-210 antibodies with Scil Biomedicals GmbH...
...acquisition by F. Hoffmann-La Roche . The president of Scil Technology Holding, the parent of Scil Biomedicals...